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Abstract 
Aims: The transcription factor CCAAT/enhancer binding protein α (C/EBPα) and microRNA (miRNA) let-7a-1 act 
as tumor suppressors in many types of cancers including lung cancer. In the present study, we aim to investigate 
whether let-7a-1 is a novel important target of C/EBPα in lung cancer cells.
Methods: The DNA sequence of the 2.1 kb let-7a-1 promoter was analyzed with MatInspector 4.1 (http://www.geno-
matix.de). Human lung cancer cell lines A549 and H1299, and human cervical cancer cell line Hela were used for trans-
fection. Total RNA was extracted from cells using Trizol reagent and pri-let-7a-1 mRNA expression was measured using 
quantitative real-time polymerase chain reaction. Western blotting was performed to detect C/EBPα protein expres-
sion. To test whether C/EBP-α could up-regulate the expression level of let-7a at transcription level, dual-luciferase 
reporter gene assay was carried out. To determine whether C/EBPα could bind let-7a-1 promoter, electrophoretic 
mobility shift assay was employed. To further confirm the direct targeting let-7a-1 promoter by C/EBPα, chromatin 
immunoprecipitation was used.
Results: Both C/EBPα and let-7a-1 were down-regulated in lung cancer A549 and H1299 cells, but up-regulated in 
Hela cells. Transfection and reporter gene assay showed that C/EBPα increased the expression of let-7a-1 at tran-
scription level. Bioinformatics assay identified four putative C/EBP elements within let-7a-1 promoter. Dual-luciferase 
reporter gene, electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrated that 
these four elements mediated the up-regulation effect of C/EBPα on let-7a-1.
Conclusions: The present study reveals that decreased C/EBPα contributes to the down-regulation of miRNA let-7a-1 
in lung cancer cells.
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Background
MicroRNA (miRNA) let-7 family plays pivotal roles in 
regulating carcinogenesis [1]. The let-7 family functions 
as tumor suppressors in multiple tumor types. They can 
inhibit the expressions of multiple oncogenes, including 
rat sarcoma viral oncogene homolog (RAS), high mobil-
ity group AT-hook 2 (HMGA2) and v-myc avian mye-
locytomatosis viral oncogene homolog (MYC) [2–4]. 
Down-regulation of let-7 family members is observed 
in multiple carcinomas, especially in lung cancer [5–7]. 
Therefore, the mechanism of down-regulation of let-7 
family members in various cancers needs to be eluci-
dated, and will help understand the regulation mecha-
nism of let-7 in carcinogenesis.
Humans have 13 let-7 family members [8], includ-
ing let-7a-1, let-7a-2, let-7a-3, let-7b, let-7c, let-7d, let-
7e, let-7f-1, let-7f-2, let-7g, let-7i, miR-98, and miR-202, 
which are located in nine different loci on chromosomes 
3, 9-12, 19, 21, 22, and X. A total of ten mature let-
7-family sequences are produced from the 13 precursor 
sequences. For example, pre-let-7a-1, pre-let-7a-2 and 
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pre-let-7a-3 produce mature let-7a, while pre-let-7f-1 
and pre-let-7a-2 produce mature let-7f. At transcriptional 
level, it has been reported that let-7 family members can 
be inhibited by oncogenic transcription factor MYC in 
lymphoma and hepatocellular carcinoma cells [9, 10]. It 
is also shown that transcriptional repressor jumonji AT-
rich interactive domain 1B (JARID1B) protein binds to 
let-7e promoter, leading to the repression of let-7e and 
the promotion of breast tumor cell cycle [11]. In addition, 
nuclear factor-kappa B (NF-κB) can enhance the tran-
scription of let-7a-3/let-7b cluster in Hela cells [12]. At 
posttranscriptional level, the main regulation factor for 
let-7 family members is lin28, which blocks the matura-
tion of pri-let-7 by binding the loop region of the pri-let-7 
stem-loop [13, 14]. However, the understanding about 
the regulation of let-7 is still limited. Three let-7 family 
members, let-7a-1, let-7f-1 and let-7d-1, form an inter-
genic miRNA cluster on chromosome 9p22.32, which is 
encoded by a single polycistronic transcript driven by a 
single promoter. The three members are the most abun-
dant species of let-7 family, together accounting for about 
24 % of all let-7 precursors [5, 15]. In addition, let-7a-1 is 
reported to be down-regulated in lung cancer, suppress-
ing the proliferation of lung cancer cells by its overex-
pression [3, 5].
The CCAAT/enhancer binding protein α (C/EBPα) 
is a differentiation-inducing transcription factor that 
belongs to a family of basic region leucine zipper (bZIP) 
transcription factors, which includes six members (α, β, 
γ, δ, ε and ζ) [16]. C/EBPα is required for proper control 
of adipogenesis, glucose metabolism, granulocytic differ-
entiation, and lung development. Many studies demon-
strate that C/EBPα indeed acts as a tumor suppressor in 
a number of tumor types [17]. In order to better under-
stand the regulation of let-7a-1 in lung cancer cells, we 
cloned a 2.1 kb promoter fragment of let-7a-1 and made 
the preliminary analysis on its function in our previ-
ous work [18]. Our previous study shows that C/EBPα 
enhances the promoter activity of let-7a-1 [18]. Although 
a growing number of studies have demonstrated the reg-
ulation of specific miRNAs by C/EBPα [19–25], it is still 
unknown whether let-7 is the target of C/EBPα. In the 
present study, we investigate the influence of the C/EBPα 
on let-7a-1 regulation in lung cancer cells.
Methods
Bioinformatics
The DNA sequence of the 2.1 kb let-7a-1 promoter was 
analyzed with MatInspector 4.1 (http://www.genomatix.
de). The MatInspector 4.1 software identifies putative 
transcription factor binding sites with weight matrices 
representing consensus recognition sequences for differ-
ent transcription factors as defined in the MatInspector 
library [26]. Four CCAAT/enhancer binding protein sites 
upstream of the let-7a-1 start site were identified. They 
were termed CEBP1-4 in this work, respectively.
Cells
Human lung cancer cell lines A549 and H1299, and 
human cervical cancer cell line Hela were obtained 
from Shanghai Institute of Biochemistry and Cell Biol-
ogy, Chinese Academy of Science (Shanghai, China) and 
maintained in RPMI1640, F-12  K and DMEM (GIBCO, 
Thermo Fisher Scientific, Waltham, MA, USA) medium, 
respectively, supplemented with 10 % fetal bovine serum 
(FBS; GIBCO, Thermo Fisher Scientific, Waltham, MA, 
USA), in a humidified atmosphere with 5 % CO2 at 37 °C. 
Within 24  h of passage, all cells with more than 90  % 
confluence were used for transfection. X-tremeGENE 
HP (Roche, Mannheim, Germany) or Lipofectamin 2000 
Transfection Agent (Thermo Fisher Scientific, Waltham, 
MA, USA) was used for plasmid or siRNA transfec-
tion, respectively, according to the manufacturer’s 
instructions.
Plasmids
A 2.1-kb let-7a-1 promoter was cut from pGL3-2123 that 
was constructed in our previous work [18], and cloned 
into pGL4.10 [luc2] vector (Promega, Fitchburg, WI, 
USA) between Xho I and Hind III sites to form pGL4.10-
2123. Four wild-type and mutant CEBP elements as 
well as CEBP consensus sequences were synthesized 
(Table  1). The double-stranded sequences were gener-
ated by annealing equal amounts of sense and antisense 
sequences at 95 °C for 10 min, and then cooling to room 
temperature. The double-stranded sequences with over-
hanging Xho I (tcgag) and Hind III (agctt) sites were 
inserted into the 5′ end of the luciferase gene in pGL4.23 
[luc2/minP] vector to generate pGL4.23-CEBP1-4w/m, 
respectively. In the same way, the target sequence of let-
7a (5′-UGAGGUAGUAGGUUGUAUAGUU-3′) was 
synthesized and inserted into sac I and Hind III sites 
of pMIR-Report luciferase reporter vector (Ambion, 
Thermo Fisher Scientific, Waltham, MA, USA) to gener-
ate pMIR-let7aT plasmid. All of the constructs were con-
firmed by DNA sequencing.
Small interfering RNA (siRNA)
To knock down the expression of C/EBPα, Hela cells 
were transfected with si-h-C/EBPα-002 (RiboBio, Guang-
zhou, China) using Lipofectamine 2000 (Invitrogen, 
Thermo Fisher Scientific, Waltham, MA, USA). Non-
targeting control siRNA (RiboBio, Guangzhou, China) 
and transfection reagents only (mock transfection) were 
transfected as negative controls. The siRNA was diluted 
to 50  nM in Opti-MEM I reduced-serum medium 
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(Invitrogen, Thermo Fisher Scientific, Waltham, MA, 
USA). After transfection for 48 h, cells were collected to 
confirm the effect of C/EBPα knockdown at both mRNA 
expression levels and protein expression levels.
Quantitative reverse‑transcription polymerase chain 
reaction (qRT‑PCR)
Total RNA was extracted from cells using Trizol reagent 
(Invitrogen, Thermo Fisher Scientific, Waltham, MA, 
USA) according to the manufacturer’s instructions. First 
strand cDNA was synthesized using a Revert Aid First 
Strand cDNA Synthesis Kit (Fermentas, Thermo Fisher 
Scientific, Waltham, MA, USA). The qRT-PCR amplifica-
tion of pri-let-7a-1 was performed according to a previ-
ous method [5].
Western blotting
Western blotting was performed to detect C/EBPα pro-
tein expression. Whole-cell lysates were prepared using 
lysis buffer [containing 50  mmol/L Tris-Cl (pH 8.0), 
150  mmol/L NaCl, 0.1  % SDS, 1  %NP-40 and 100  mg/
ml PMSF]. Protein concentration was determined using 
Bradford assay (Bio-Rad, Hercules, CA, USA). Extracted 
protein (30  μg) was processed in a 10  % SDS-PAGE gel 
and transferred to a polyvinylidene fluoride membrane. 
Protein levels of C/EBPα were measured by antibody 
raised against the C-terminus of human C/EBPα (sc-
9314X, Santa Cruz Biotechnology, Dallas, TX, USA). 
Anti-β-Actin (Sigma, St. Louis, MO, USA) was used as 
an internal control. Immunoblots were detected using an 
enhanced chemiluminescence kit (Santa Cruz Biotech-
nology, Dallas, TX, USA) and visualized after exposure to 
X-ray film.
Dual‑luciferase reporter gene assay
Cells in 70–80  % confluence were co-transfected in 
24-well plates. Each well contained 0.3 μg reporter gene 
plasmid, 0.02  μg of the internal control vector pGL4.74 
[hRluc/TK] vector (Promega, Fitchburg, WI, USA), 
1  μl transfection agent, and 0.2  μg expression vector or 
si-RNA. At 48  h after the completion of the transfec-
tion procedure, all the cells underwent dual-luciferase 
reporter assay, following the protocol recommended by 
the manufacturer’s manual. The cells were lysed using 
1× reporter lysis buffer and harvested by manual scrap-
ing. Luminescence was detected using a Mithras LB 940 
(Berthold Technologies, Oak Ridge, TN, USA). The fire-
fly luciferase activity of the reporter gene plasmid was 
measure 1 (M1), and the renilla luciferase activity (inter-
nal control) of pGL4.74 [hRluc/TK] vector was measure 2 
(M2). The relative luciferase activity was calculated as the 
ratio of M1/M2.
Electrophoretic mobility shift assay (EMSA)
At 24 h before transfection, H1299 cells were inoculated 
in 6-well plate. When in 70–80 % confluence, each well 
was transfected by 0.2  μg pcDNA3.1(+)-C/EBPα. At 
48 h after transfection, the cells were collected and pre-
pared for nuclear extracts as described previously [27]. 
Double-stranded oligonucleotide probes were obtained 
by annealing sense and antisense sequences (Table  2). 
Probes were end-labeled with digoxin using T4 polynu-
cleotide kinase (Invitrogen, Thermo Fisher Scientific, 
Table 1 Oligonucleotide sequences used for reporter gene assay
Name Sequences (5′–3′)
CEBP consensus wild-type (CEBPcw) Sense, tcgagTGCAGATTGCGCAATCTGCAa; anti-sense, agcttTGCAGATTGCGCAATCTGCAc
CEBP consensus mutant (CEBPcm) Sense, tcgagTGCAGAGACTAGTCTCTGCAa; anti-sense, gcttTGCAGAGACTAGTCTCTGCAc
CEBP consensus wild-type (CEBP1w) Sense, tcgagGAGGTTGTGAAACCCa; anti-sense, agcttGGGTTTCACAACCTCc
CEBP consensus mutant (CEBP1 m) Sense, tcgagGAGGGAGTAAGCCCCa; anti-sense, agcttGGGTTTCACAACCTCc
CEBP2 wild-type (CEBP2w) Sense, tcgagTGTGTTCTGTAAGCCa; anti-sense, agcttGGCTTACAGAACACAc
CEBP2 mutant (CEBP2 m) Sense, tcgagTGTGGTCTATGCGCCa; anti-sense, agcttGGCGCATAGACCACAc
CEBP3 wild-type (CEBP3w) Sense, tcgagTACGTTTTGTAATTTa; anti-sense, agcttAAATTACAAAACGTAc
CEBP3 mutant (CEBP3 m) Sense, tcgagTACGGTTTATGCTTTa; anti-sense, agcttAAAGCATAAACCGTAc
CEBP4 wild-type (CEBP4w) Sense, tcgagAAGATTCAGAAATCAa; anti-sense, agcttTGATTTCTGAATCTTc
CEBP4 mutant (CEBP4 m) Sense, tcgagAAGAGTCAAAGCTCAa; anti-sense, agcttTGAGCTTTGACTCTTc
Table 2 Oligonucleotide sequences used for  electropho-




CEBP2 (−1684/−1670) 5′- tccTGTGTTCTGTAAGCCatc-3′
CEBP3 (−722/−708) 5′-tatTACGTTTTGTAATTTtaa-3′
CEBP4 (−163/−149) 5′-tacAAGATTCAGAAATCAccc-3′
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Waltham, MA, USA). EMSA was performed using the 
DIG Gel Shift Kit (Second Generation; Roche, Basel, 
Switzerland) following the manufacturer’s protocol. Anti-
bodies against C/EBPα (sc-9314x; Santa Cruz Biotech-
nology, Dallas, TX, USA) was used for supershift assay.
Chromatin immunoprecipitation (ChIP)
At 24 h before transfection, H1299 cells were inoculated 
in 10-cm dishes. When in 70–80  % confluence, each 
well was transfected by 2  μg pcDNA3.1(+)-C/EBPα or 
pcDNA3.1(+). At 48 h after transfection, the cells were 
collected and ChIP assay was performed using ChIP 
Assay Kit (Millippore, Billerica, MA, USA) following 
the manufacturer’s protocol. For each immunoprecipita-
tion reaction, 106 H1299 cells and 2  μg of goat anti-C/
EBPα (sc-9314x; Santa Cruz Biotechnology, Dallas, TX, 
USA) or control IgG (Santa Cruz Biotechnology, Dal-
las, TX, USA) were used. The immunoprecipitated DNA 
was recovered and used as template for PCR using three 
pairs of primers complementary to the region flank-
ing the C/EBPα motifs in let-7a-1 promoter (Table  3). 
The products were resolved on agarose gel, purified 
and sequenced. An aliquot of sheared chromatin DNA 
was subjected to PCR before immunoprecipitation and 
served as input control.
Statistical analysis
All data were analyzed using SPSS 17.0 software package 
(IBM, Armonk, NY, USA). All values were expressed as 
mean ± standard deviation from at least three independ-
ent experiments. Statistical significance was defined as 
P < 0.05.
Results
Positive correlation may exist between the expression 
levels of C/EBPα and pri‑let‑7a‑1
To determine the expression levels of C/EBPα and pri-
let-7a-1, western blotting and qRT-PCR were used, 
respectively. The data showed that C/EBPα and pri-let-
7a-1 levels in A549 cells were significantly higher than 
that in H1299 cells, but were significantly lower than that 
in Hela cells (Fig. 1a, b). The result suggests that positive 
correlation may exist between the expression levels of C/
EBPα and pri-let-7a-1.
C/EBPα expression affects the promoter activity of let‑7a‑1 
in a dose‑dependent manner
To study how C/EBPα expression affects the pro-
moter activity of let-7a-1, we performed reporter gene 
assay. The data showed that ectopic C/EBPα expression 
increased the promoter activity of let-7a-1 significantly 
in H1299 cells in a dose-dependent manner, reaching the 
maximal 5.11-fold at 0.05  μg vector transfection After 
that, the effect was weaken as the continued increase of 
transfection doses (Fig.  2). This result indicates that C/
EBPα expression affects the promoter activity of let-7a-1 
in a dose-dependent manner.
C/EBP‑α up‑regulates the expression level of let‑7a 
at transcription level
To further investigate whether the expression of let-
7a-1 could be influenced by C/EBPα, H1299 cells were 
transfected with C/EBPα expression vector, while Hela 
cells were transfected with si-C/EBPα. First, the over-
expression and knockdown of C/EBPα were confirmed 
Table 3 Oligonucleotide sequences used for polymerase chain reaction primers in chromatin immunoprecipitation assay
Name Sequences Fragment lengths
CEBP1/2 Forward, 5′-ACAAACTTCACAGGTTGAGGGC-3′ reverse, 5′-TAATAAACCAGTGATAATGAGTGTCTTC-3′ 184 bp
CEBP3 Forward, 5′-CAGCCGTCAGCATTATTTGT-3′ reverse, 5′-CGAAGATTATCTTTTAAGATAGGGA-3′ 220 bp
CEBP4 Forward, 5′-GTAAAAGGTGGTGGTAAGAGGGT-3′ reverse, 5′-ACATGCATAATCTATGCTGTGGTT-3′ 135 bp
Fig. 1 Expression of C/EBPα and let-7a-1. Detection of (a) C/EBPα 
protein (30 μg) expression and (b) let-7a-1 was performed by western 
blotting and quantitative real-time polymerase chain reaction, 
respectively, in Hela, A549 and H1299 cells. Data are represented as 
means ± standard deviations from three independent tests. *P < 0.05
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by western blotting analysis (Fig.  3a). In addition, over-
expression of C/EBPα increased the expression level 
of pri-let-7a-1 by 3.97-fold in H1299 cells (Fig.  3b), 
whereas knockdown of C/EBPα decreased the expres-
sion level of pri-let-7a-1 by about 50  % in Hela cells 
(Fig.  3c). Meanwhile, luciferase reporter assay showed 
that ectopic expression of C/EBPα significantly reduced 
luciferase activity in H1299 cells transfected with pMIR-
7aT (Fig.  3d), while knockdown of C/EBPα significantly 
increased luciferase activity in Hela cells with si-C/EBPα 
transfection (Fig. 3e). These results suggest that C/EBP-α 
up-regulates the expression level of let-7a at transcription 
level.
The let‑7a‑1 gene promoter contains potential binding 
sites for C/EBPα
According to MatInspector with Matrix Similar-
ity 0.85 and Matrix Family Library, there are four C/
EBP potential binding sites within 2.1  kb of human let-
7a-1 promoter upstream of the transcription start site. 
These four C/EBP potential binding sites were termed 
as CEBP1/2/3/4, where CEBP1/2 sites were in tandem 
within a 57-bp sequence (−1726/−1670) (Fig. 4a). After 
wild-type and mutant sequences of CEBP1/2/3/4 ele-
ments as well as C/EBPα consensus sequence (CEBPcw/
cm) were synthesized and inserted into reporter gene 
vector, the constructs were used to investigate the func-
tion and importance of these C/EBPα binding sites for 
let-7a-1 gene expression using dual-luciferase reporter 
gene assay. All of the plasmid constructs were transiently 
co-transfected into H1299 cells with pcDNA3.1(+)-C/
EBPα, using pcDNA3.1(+) as control. Compared to co-
transfection with pcDNA3.1(+), all wild-type C/EBP 
elements co-transfected with pcDNA3.1(+)-C/EBPα pre-
sented significantly increased luciferase activity. Moreo-
ver, the increase of C/EBP elements within let-7a-1 was 
higher than C/EBP consensus. However, mutant C/EBP 
elements displayed insignificant change in luciferase 
activity in response to the ectopic expression of C/EBPα 
(Fig.  4b). These results indicate that let-7a-1 gene pro-
moter contains potential binding sites for C/EBPα.
C/EBPα can bind let‑7a‑1 promoter as demonstrated 
by EMSA
To determine whether these putative C/EBP elements are 
capable of binding transcription factor C/EBPα in vitro, 
we performed a series of EMSA experiments with nuclear 
extracts from H1299 cells with ectopic C/EBPα expres-
sion, using C/EBP consensus sequence as positive con-
trol. All of the four CEBP probes and C/EBP consensus 
sequence showed transcription factor binding activity. 
Furthermore, these complexes were blocked specifically 
by anti-C/EBPα antibody and were effectively competed 
by cold competitor oligonucleotides (Fig.  5). The result 
suggests that C/EBPα can bind let-7a-1 promoter.
The let‑7a‑1 promoter is a direct transcriptional target of C/
EBPα as determined by ChIP assay
In order to further confirm that C/EBPα indeed binds 
to let-7a-1 promoter, we performed endogenous ChIP. 
First, C/EBPα proteins were immunoprecipitated from 
DNA–protein cross-linked cell lysates. After the removal 
of all proteins, the recovered DNA was precipitated by 
ethanol and amplified by PCR using primers specific 
for let-7a-1 promoter. In contrast to H1299 cells trans-
fected with pcDNA3.1(+), H1299 cells transfected with 
pcDNA3.1(+)-C/EBPα showed that all of four C/EBP 
sites within let-7a-1 promoter were indeed associated 
with C/EBPα immunoprecipitates (Fig.  6, lanes 4–6), 
whereas a IgG negative control failed to precipitate any 
let-7a-1 promoter DNA (Fig.  6, lanes 7–9). The result 
indicates that let-7a-1 promoter is a direct transcriptional 
target of C/EBPα.
Discussion
miRNAs are a group of gene regulators that play impor-
tant roles in biologic processes such as cell prolifera-
tion, differentiation, and apoptosis. The dysregulation 
of miRNAs is associated with the development of can-
cers, including lung cancer [5, 28, 29]. Many evidences 
have indicated that miRNA genes are transcribed by 
RNA polymerase II, and only a few miRNA promot-
ers in H. sapiens have been identified so far. As class II 
genes, expressions of many miRNAs are also regulated by 
enhancers or hormones [30–32]. As a result, one of the 
reasons for the dysregulation of miRNAs in tumor tissues 
or cells may be the dysregulation at transcription level.
C/EBPα is a basic leucine zipper transcription factor that 
is expressed in many tissues, and plays an important role 
Fig. 2 Effect of ectopic C/EBPα expression on promoter activity of 
let-7a-1 in H1299 cells. Data are represented as means ± standard 
deviations from three independent tests. *P < 0.05; **P < 0.005
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in regulating the balance between cell proliferation and 
cell differentiation [17, 33]. Loss of C/EBPα functions has 
been linked to leukemogenesis, lung cancer, liver cancer, 
etc., suggesting an important role for C/EBPα as a tumor 
suppressor [34, 35]. A growing number of studies have 
demonstrated the regulation of specific miRNAs by C/
EBPα. Fazi et al. first identify miR-223 as a direct target of 
C/EBPα, and C/EBPα-induced up-regulation of miR-223 
Fig. 3 Effect of C/EBPα on the expression of let-7a-1. a Detection of ectopic C/EBPα overexpression in H1299 cells and knockdown in Hela cells by 
western blotting. For each sample, 30 μg total proteins were used. Detection of (b) induction of pri-let-7a-1 by ectopic C/EBPα expression in H1299 
cells, and (c) reduction of pri-let-7a-1 by C/EBPα knockdown in Hela cells. Quantitative real-time polymerase chain reaction was performed to detect 
the level of pri-let-7a-1. Data are represented as means ± standard deviations from three independent tests. *P < 0.05. Detection of (d) let-7a induc-
tion by ectopic C/EBPα expression in H1299 cells, and (e) let-7a reduction by ectopic c/EBPα knockdown in Hela cells by Dual-luciferase reporter 
gene assay. Data are represented as means ± standard deviations from three independent tests. *P < 0.05
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leads to granulopoiesis [19]. Zeng et  al. report that C/
EBPα directly interacts with miR-122 (hepatocyte-specific 
miRNA) promoter and transactivates it [20]. Moreover, 
recent studies show that several tumor suppressor miRNAs 
are directly regulated by C/EBPα, such as miR-223, miR-
34a and miR-30C, and that transactivation of all miRNAs 
Fig. 4 Four potential binding sites for C/EBPα in let-7a-1 gene promoter. a Schematic representation of four examined putative C/EBP binding sites 
in the promoter region of let-7a-1 predicted by MatInspector software. b Detection of the functions of four putative C/EBP elements by reporter 
gene assay. After wild-type and mutant sequences of CEBP1/2/3/4 elements as well as C/EBPα consensus sequence (CEBPcw/cm) were synthesized 
and inserted into reporter gene vector, the constructs were used to investigate the function and importance of these C/EBPα binding sites for let-
7a-1 gene expression using dual-luciferase reporter gene assay. All of the plasmid constructs were transiently co-transfected into H1299 cells with 
pcDNA3.1(+)-C/EBPα, using pcDNA3.1(+) as control
Fig. 5 Binding of the four C/EBP elements with C/EBPα. EMSA experiments were performed with nuclear extracts from H1299 cells with ectopic C/
EBPα expression, using C/EBP consensus sequence as positive control
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is inhibited along with the down-regulated expression of 
C/EBPα [21–23]. In A549 and H1299 lung cancer cells, 
ectopic C/EBPα expression increases the expression of 
miR-1 by 6.1 and 4.92-fold, respectively [24]. miR-661 is 
another C/EBPα target [25].
Our previous study shows that C/EBPα enhances the 
promoter activity of let-7a-1 gene in lung cancer A549 
cells [18]. In the present study, we identify that let-7a-1 
gene is another new target of C/EBPα. We first exam-
ined the association between pri-let-7a-1 and C/EBPα 
expression. The expression levels of C/EBPα and pri-
let-7a-1 are found to be down-regulated in several lung 
cancer cell lines [5, 36], whereas Hela cells have high 
level of let-7 expression. Therefore, we selected lung 
cancer cell lines A549 and H1299, as well as and Hela 
cells to detect expression levels of the two by qRT-PCR 
and western blotting. The results show that pri-let-7a-1 
level is positive correlated with C/EBPα expression. Fur-
thermore, the ectopic expression of C/EBPα increases 
pri-let-7a-1 level in H1299 cells, while RNA interference 
for C/EBPα decreases pri-let-7a-1 level in Hela cells. 
The results demonstrate that C/EBPα transactivates the 
expression of let-7a-1 gene. Based on the fact that let-
7a-1 is the most abundant specie of let-7a subfamily, 
reporter gene assay is performed to observe the effect 
of C/EBPα on mature-let-7a expression. Dual-luciferase 
detection shows that ectopic expression of C/EBPα 
increases mature-let-7a level in H1299 cells, while RNA 
interference for C/EBPα decreases mature-let-7a level 
in Hela cells. Moreover, reporter gene assay performed 
in H1299 cells has displayed that ectopic expression of 
C/EBPα increases promoter activity of let-7a-1, being in 
accordance with our previous result [18]. Therefore, the 
transcription factor C/EBPα can up-regulate the expres-
sion of let-7a-1 gene at transcription level.
Bioinformatics assay has identified four putative C/
EBP elements within let-7a-1 promoter. We infer that at 
least one of them may mediate the transactivation effect 
of C/EBPα. To confirm this, luciferase activity assay was 
performed in H1299 cells to analyze the function of the 
four putative CEBP elements. The results showedthat all 
of the four elements respond to ectopic expression of C/
EBPα, and their luciferase activities are higher than that 
of C/EBP consensus sequence used as positive control. 
Among them, CEBP3 element has displayed the high-
est activity. Furthermore, in  vitro binding assay shows 
that all of the four C/EBP elements and C/EBP consen-
sus sequence have binding capacity with nuclear protein 
extracted from H1299 cells with ectopic C/EBPα expres-
sion. In addition, these binding complexes can be blocked 
by anti-C/EBPα antibody specifically. At last, ChIP assay 
demonstrates the direct interaction between C/EBPα and 
the four C/EBP elements. In summary, the present study 
identifies tumor suppressor miRNA let-7a-1 gene as a 
new direct target of transcription factor C/EBPα. Our 
results conclude that decrease or absence of tumor sup-
pressor C/EBPα contributes to the transcriptional inhibi-
tion of let-7a-1.
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Fig. 6 Targeting of let-7a-1 promoter by C/EBPα. ChIP assay was performed on H1299 cells transfeted with pcDNA3.1(+) or pcDNA3.1(+)-C/EBPα. 
C/EBPα proteins were immunoprecipitated from DNA–protein cross-linked cell lysates. After the removal of all proteins, the recovered DNA was 
precipitated by ethanol and amplified by PCR using primers specific for let-7a-1 promoter
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